Your browser doesn't support javascript.
loading
T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.
Mori, Hitomi; Kubo, Makoto; Kai, Masaya; Yamada, Mai; Kurata, Kanako; Kawaji, Hitomi; Kaneshiro, Kazuhisa; Osako, Tomofumi; Nishimura, Reiki; Arima, Nobuyuki; Okido, Masayuki; Kishimoto, Junji; Oda, Yoshinao; Nakamura, Masafumi.
Afiliación
  • Mori H; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
  • Kubo M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan. mkubo@tumor.med.kyushu-u.ac.jp.
  • Kai M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
  • Yamada M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
  • Kurata K; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
  • Kawaji H; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
  • Kaneshiro K; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
  • Osako T; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, 3-2-65 Oe Chuo-ku, Kumamoto, 862-8655, Japan.
  • Nishimura R; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, 3-2-65 Oe Chuo-ku, Kumamoto, 862-8655, Japan.
  • Arima N; Department of Pathology, Kumamoto Shinto General Hospital, 3-2-65 Oe Chuo-ku, Kumamoto, 862-8655, Japan.
  • Okido M; Breast Center, Hamanomachi Hospital, 3-3-1 Nagahama Chuo-ku, Fukuoka, 810-8539, Japan.
  • Kishimoto J; Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
  • Oda Y; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
  • Nakamura M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.
Breast Cancer Res Treat ; 176(3): 569-577, 2019 Aug.
Article en En | MEDLINE | ID: mdl-31069590
ABSTRACT

PURPOSE:

T-box transcription factor 21 (T-bet), which is the master regulator of effector T-cell activation, is derived by stimulation of T-cell receptors. In this study, we focused on T-bet and examined the function of activated T cells.

METHODS:

This study included 242 patients with primary triple-negative breast cancer (TNBC) who underwent resection without neoadjuvant chemotherapy between January 2004 and December 2014. The immunohistochemistry scoring for CD8 and T-bet expression on tumor-infiltrating lymphocytes (TILs) was defined as ≥ 30 per 6.25 × 10-3 mm2.

RESULTS:

Of the 242 TNBC cases, CD8 was positively expressed in 127 (52.5%) tumors, and T-bet was positively expressed in 67 (27.7%) tumors. T-bet expression was significantly correlated with CD8 expression (p < 0.0001). Patients with T-bet+ tumors had longer overall survival (OS) compared with patients with T-bet- tumors (p = 0.047). The combination of CD8+ and T-bet+ was associated with a better recurrence-free survival (RFS) and OS compared to CD8+/T-bet- tumors (p = 0.037 and p = 0.024, respectively). Adjuvant chemotherapy provided significantly greater benefit to patients with T-bet+ tumors (p = 0.031 for RFS, p = 0.0003 for OS). Multivariate analysis revealed that T-bet expression on TILs was an independent and positive prognostic indicator (HR = 0.36, 95% confidence interval (CI) 0.12-0.94, p = 0.037 for RFS, HR = 0.30, 95% CI 0.07-0.95, p = 0.039 for OS).

CONCLUSIONS:

OS was significantly improved for patients with high T-bet-expressing TILs in TNBC. Thus, T-bet may be a predictive indicator for survival and various immunotherapy strategies in TNBC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Subgrupos de Linfocitos T / Linfocitos Infiltrantes de Tumor / Proteínas de Dominio T Box / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Subgrupos de Linfocitos T / Linfocitos Infiltrantes de Tumor / Proteínas de Dominio T Box / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article País de afiliación: Japón
...